Tremelimumab (day 1 only) and durvalumab in combination with transarterial chemoemobilization (TACE) in patients with hepatocellular carcinoma (HCC).

• DOI: 10.1200/jco.2022.40.4_suppl.451
• Publication Date: 2022-01-19T20:44:02Z
• Authors: Jemma Buchalter; Iseult Browne; Colm Mac Eochagain; Calvin Flynn; Hailey Kathryn Ca...; Marie Galligan; Michele Bourke; Amy Lester-Grant; Fiona Desmond; Katherine Hoey; Ronan Ryan; Colin P Cantwell; Jeffrey McCann; Ray McDermott; Ross MacNicholas; Austin G Duffy
• Keywords: Tremelimumab; Durvalumab

451 Background: TACE induces a peripheral anti-tumor immune response, which may be amplified by checkpoint inhibitors (ICI). Combining with dual ICI therapy has been shown to safe and feasible. Recent data suggested that Day 1-only anti-CTLA4 dosing could potentially lead stronger response tolerable safety profile though this novel schedule not previously combined TACE. Methods: Patients HCC (Childs Pugh A/B7, Barcelona clinic liver cancer stage B/C; ECOG 0/1; sorafenib-naive or experienced) were enrolled in pilot study of tremelimumab at 2 dose levels (DL1: 75mg IV q4-weekly x 4 DL2: 300mg D1 only) combination durvalumab (1500mg q-28d) (D36 +/- 96 hours) until progression disease (per irRECIST) off-study criteria. Peripheral monitoring was performed tumor biopsies obtained time Results: 13 patients on study; N = 3 DL1 10 DL2. M:F 10:3. Median age 70 (65-74). BCLC B/C 4/9. Extrahepatic 6/7. Aetiology: NASH (N 3), alcohol-related 1), HCV 2), hemochromatosis unknown 6). 1 patient discontinued due G3 colitis. All evaluable for 2/10 DL2 experiencing PR (at 8 weeks) overall 8/13 SD 3/13 PD as best response. Updated PFS OS presented. Conclusions: Tremelimumab (Day Durvalumab is feasible HCC. Follow-up ongoing full efficacy will Clinical trial information: 2019-002767-98.